Skip to content
‹ Back to IndustriesSciences

What Can the Pharma Industry Learn from Merck’s New Antiviral?

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs. For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding. Work on the related compound was…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · · AntiviralLsuMerckPharmaceutical Production Pipeline
Share

Key takeaways

01

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs.

02

For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding.

03

Work on the related compound was…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs. For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding. Work on the related compound was active at Emory University as far back as 2004, with millions

With that kind of federal investment, and Operation Warp Speed validating the role of the federal government in supporting critical biomedical development, we wanted to know: can the industry expect any further involvement, financial or regulatory, from the federal government around COVID treatments? Plus, as Operation Warp Speed accelerated the COVID vaccine research timeline, are there more sustainable ways to bring this level of turnaround to other parts of the pharmaceutical pipeline without lags in treatment quality or oversight?

MarketScale sourced Dr. Kishor M. Wasan, Chief Medical and Scientific Officer at Skymount Medical, for his perspective, pulling from his active research around drug production and AI. Scroll down for his various insights!

1. Do the Successes of Operation Warp Speed Validate the Support of the Federal Government?

2. How LSU Designed a Model to Speed Up the Evaluation of Drug Candidates

3. How the Pharmaceutical Pipeline can Balance Speed and Quality

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million ADVANCE lab in West Point, Pennsylvania, which opened in October 2026, reserved floor space for robots before some of them had final dimensions. Containment sits inside robotic work cells, space and utilities were sized for the largest expected machines, and validation waited until construction ended. Other lab capital projects can reuse that order of work.

  • 01When robotic platforms carry their own enclosures, walls are needed mainly where the science or access control demands them, and the open floor plan is designed to make future equipment swaps easier without automatically forcing new room build-outs.
  • 02Merck planned for the largest expected robot sizes and highest utility needs, using lessons from its 2023 Spring House lab, according to Lab Design News. Teams without a previous project to learn from could find those limits harder to set.

Nov 21, 2026

Keller’s case for carbs as key fuel for post-workout muscle repair

Keller’s case for carbs as key fuel for post-workout muscle repair

In a NuLiv Science segment, nutrition scientist and dietitian Dr. Rosa Keller argues that carbohydrate (glucose) is a key fuel for mitochondrial ATP after resistance training and that clients often under-eat carbs. The article cites reviews emphasizing carbohydrate for glycogen restoration (including John Ivy’s 1.2 g/kg/hour post-exercise target), describes protein as a co-ingested partner in recovery, and notes ketogenic-diet findings that may benefit aging mitochondria.

  • 01John Ivy's post-exercise carbohydrate target is about 1.2 grams per kilogram of body weight per hour, taken early and often, to maximize glycogen resynthesis.
  • 02Nature Metabolism describes carbohydrate as the primary fuel for ATP in most Olympic events, and Keller argues that post-exercise repair depends on mitochondria having fuel to generate ATP.
  • 03Ketogenic diets improve muscle mitochondrial mass and function with age or disease but not in athletes, Pathak and Baar concluded, so the carbohydrate rule depends on who is training.

Nov 20, 2026

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread has launched a Model Context Protocol server that lets scientists query their lab records from ChatGPT, Claude or other AI assistants. The server runs inside Lab Thread's cloud with audit logs aligned to 21 CFR Part 11, so the audit trail stays with the record system. The company also opened a Boston office.

  • 01For a regulated lab, the useful question about any AI connector is where the audit log lives. Lab Thread keeps it inside its own tenant-isolated cloud and shares only the minimum context each authorized query needs.
  • 02Pinning an MCP server version doesn’t lock its transitive dependencies, so the code that runs can still change between builds. If Lab Thread’s MCP server is vendor-hosted in its secure cloud, the local install/package chain would be the vendor’s to manage rather than something each scientist launches on a laptop.
  • 03Before connecting an assistant, ask what the audit log records for each AI query: the user, the records touched and the context sent outside the platform.

Nov 20, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Daniel Litwin
Daniel Litwin

Editor, B2B Media

MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512